Cognitive Behavioral Therapy for Insomnia (CBT-I) is the evidence-based first-line treatment and outperforms medication in long-term results. When medication is used, trazodone, suvorexant, and eszopiclone have better long-term profiles than Z-drugs or OTC antihistamines. Diphenhydramine (Benadryl/ZzzQuil) stops working within a few days and carries risks for older adults.
Medications for Insomnia: A Plain-English Guide
Chronic insomnia — defined as difficulty falling or staying asleep at least three nights per week for at least three months — affects roughly 10–15% of the adult population. It is one of the most commonly self-treated conditions, which is why the sleep aid aisle at any pharmacy is overflowing with options. The problem is that most OTC remedies are poorly matched to chronic insomnia. This guide provides an honest comparison of what works, what doesn't, and what the evidence actually says about sleep medication.
An important starting point: insomnia is not just a symptom of something else. It can exist independently as a disorder, and when it does, the most effective long-term treatment is not a pill. But medication plays a real role for many patients, and understanding the differences between options matters.
First-Line: CBT-I (Not a Medication)
Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as the first-line treatment for chronic insomnia by the American College of Physicians and the American Academy of Sleep Medicine. It is not a relaxation technique or sleep hygiene lecture — it is a structured behavioral program that includes sleep restriction therapy, stimulus control, cognitive restructuring, and relaxation training. In direct comparisons with sleep medications, CBT-I produces equal or superior short-term outcomes and significantly better long-term outcomes. Improvements persist after the program ends; medication effects stop when the drug is discontinued. CBT-I is available through trained therapists and increasingly through validated digital programs.
OTC Sleep Aids
Melatonin is a hormone the brain produces naturally in response to darkness, signaling that it is time to sleep. Supplemental melatonin is effective for circadian rhythm disorders — jet lag and shift work — because it resets the internal clock. For chronic insomnia, however, the evidence is modest at best. Insomnia is primarily a hyperarousal disorder, not a timing disorder; melatonin addresses timing, not arousal. It is safe, widely available, and worth trying, but most people with true chronic insomnia find limited benefit. The most effective doses for sleep onset are on the lower end of what is sold commercially.
Diphenhydramine is an antihistamine that causes drowsiness as a side effect — the same compound in Benadryl. It is the active ingredient in most OTC "PM" sleep products. The problem: tolerance develops within 2–4 days of nightly use, making it largely ineffective for chronic insomnia. It also has significant anticholinergic effects (dry mouth, urinary retention, constipation, next-day cognitive fog) that are particularly problematic in older adults — it appears on the Beers Criteria list of medications potentially inappropriate in older adults. It is acceptable for very occasional use, not a solution for ongoing insomnia.
Doxylamine is another antihistamine sleep aid — similar mechanism to diphenhydramine, somewhat more sedating, with the same tolerance and anticholinergic concerns. Like diphenhydramine, it develops tolerance quickly and is not appropriate for ongoing insomnia. It is sometimes used in combination products for nausea during pregnancy (as Diclegis/Bonjesta with vitamin B6), which is a different, pregnancy-specific application.
Prescription Sleep Medications
Trazodone is an antidepressant used off-label for insomnia at lower amounts than its antidepressant range. It works primarily by blocking histamine and serotonin receptors, producing sedation. It is not habit-forming, has no dependence potential, and is not a controlled substance — which makes it one of the most commonly prescribed sleep aids in the United States despite having no FDA approval specifically for insomnia. Side effects include morning grogginess, orthostatic hypotension (dizziness on standing), and priapism (rare, in men). It is generally well-tolerated and a reasonable long-term option.
Z-drugs act on GABA receptors similarly to benzodiazepines but with more selectivity for receptors involved in sleep. Zolpidem (Ambien) is among the most prescribed sleep medications in the U.S. It reduces sleep onset time effectively but carries significant risks: complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating — sometimes without any memory), next-day impaired driving (especially the CR formulation and in women), dependence with regular use, and rebound insomnia upon stopping. The FDA has required label changes to emphasize these risks. Eszopiclone (Lunesta) has a longer duration and FDA approval for longer-term use but shares similar concerns. These medications are generally intended for short-term use.
Suvorexant represents a newer mechanism: rather than sedating the brain, it blocks orexin (also called hypocretin), a neurotransmitter that promotes wakefulness. By blocking this "wake signal," it allows natural sleep to occur. This is conceptually different from older sedative-hypnotics — it removes an obstacle rather than adding sedation. It is FDA-approved for chronic insomnia and is a Schedule IV controlled substance. Studies show it is effective for both sleep onset and sleep maintenance. Next-day somnolence and sleep paralysis are possible side effects. The lack of the "sedated" feeling many patients associate with sleep aids can feel unusual at first.
Quetiapine is an atypical antipsychotic that causes significant sedation at low amounts due to histamine receptor blockade. It is widely prescribed off-label for insomnia despite not having FDA approval for this use. The controversy is real: prescribing an antipsychotic for insomnia exposes patients to risks including metabolic side effects (weight gain, elevated blood glucose), tardive dyskinesia with long-term use, and QT prolongation. Most sleep medicine specialists consider this a poor choice when better options exist, though it may be appropriate in patients who also have psychiatric conditions that independently benefit from it.
How Doctors Choose a Sleep Medication
When CBT-I is unavailable, refused, or insufficient on its own, medication selection is guided by the patient's specific insomnia pattern (trouble falling asleep vs. staying asleep), age, other medications (drug interactions), and any comorbidities. Trazodone is often a first prescription choice due to its non-habit-forming profile. Suvorexant is preferred in patients concerned about dependence or who have had problems with Z-drugs. Z-drugs may be used short-term for acute situational insomnia. Older adults should avoid diphenhydramine, benzodiazepines, and Z-drugs if possible due to fall and cognitive risks.
Zolpidem and other Z-drugs can cause complex sleep behaviors including sleepwalking and sleep-driving with no memory of the event. The FDA requires these risks to be prominently labeled. Do not drive or operate machinery if you feel residual sedation the next morning.
Frequently Asked Questions
Is it safe to take sleep aids every night?
It depends on the medication. OTC antihistamines lose effectiveness within days and have anticholinergic concerns. Z-drugs are generally approved for short-term use. Trazodone and suvorexant have been used longer-term in clinical practice with more acceptable profiles. Any nightly sleep medication use should be discussed with a doctor, and CBT-I remains a better long-term solution than any medication.
Why is melatonin considered weak evidence for insomnia?
Melatonin is effective for circadian rhythm disorders because it signals the body's internal clock. For chronic insomnia — which is primarily a hyperarousal disorder — melatonin's effects are modest at best. Most clinical trials show small improvements in sleep onset time, typically 7–12 minutes. It is safe and worth trying, particularly at lower amounts, but should not be expected to produce the same effect as a prescription sleep aid.
What is CBT-I and why do doctors recommend it over medication?
Cognitive Behavioral Therapy for Insomnia (CBT-I) is a structured program that addresses the thoughts, behaviors, and habits maintaining chronic insomnia. It includes sleep restriction therapy, stimulus control, relaxation techniques, and sleep hygiene education. Multiple head-to-head studies show it outperforms medication in long-term outcomes, and improvements persist after treatment ends. CBT-I is now available through trained therapists and validated digital programs.
Need to identify a pill by its imprint, shape, or color?
Use the PillID Pill Identifier →